Aliada Therapeutics
A USA-based neuroscience-focused company working towards overcoming the delivery hurdle in large molecule drug development.
Aliada is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness.
Latest Aliada Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze